it is not a treatment for nausea, constipation, or other GLP-1 side effects
Visca D, Pignatti P, Spanevello A, Lucini E, La Rocca E
Search strategy and study selection Search queries were developed and run across the electronic databases PubMed, Google Scholar and Science Direct, including publications from their inception up to 30 September 2024
Populations Inclusion and Exclusion Criteria Patients were eligible for inclusion if they were diagnosed with SPIGFD according to Polish criteria, i.e., they presented with extremely short stature below 3.0 SD for age and sex and they had an IGF-1 concentration below the 2.5th percentile for age and sex confirmed in nocturnal surge and/or stimulation tests
Keywords: pentadecapeptide BPC 157, isoprenaline, occlusion-like syndrome, myocardial infarction, oxidative stress, L-NAME, L-arginine, rats 1